Navigation Links
The Leukemia & Lymphoma Society and Avella Specialty Pharmacy to Present Free Event on Oral Chemotherapy Drugs

PHOENIX, Jan. 24, 2013 /PRNewswire/ -- The Arizona Chapter of The Leukemia & Lymphoma Society and Avella Specialty Pharmacy announce they will present a day of discussion about the latest advancements, trends and management of oral chemotherapy medications. The free event will take place on Feb. 9, from 10:30 a.m. to 2:30 p.m., at SkySong, the ASU Scottsdale Innovation Center, 1475 N. Scottsdale Road, Scottsdale.

Local hematology/oncology community members will provide in-depth presentations on oral chemotherapy drugs including current trends, compliance and medication management. The event will feature two breakout sessions – one for nurses wherein they can earn complimentary CE credits and the other track for cancer patients and their families – as well as a town hall-style session featuring several local experts.

"More than 35 percent of the 400 cancer drugs in the pipeline are oral chemotherapy drugs. They clearly are the wave of the future," stated John Musil , Pharm.D., founder and CEO of Avella. "However, with so many breakthroughs, it's difficult for patients to stay on top of all of them. Our partnership with The Leukemia & Lymphoma Society aligns with our mission of optimizing patient health by educating healthcare professionals and patients on these advancements. Our hope is to provide similar discussions throughout the year as there is a growing need for this type of education."

Healthcare professionals will learn about current oral chemotherapy drug trends, compliance and best practices on how to provide adequate patient surveillance and support. Eric Sredzinski , Pharm.D., AAHIVE, Pharmacy Program Director, ADAP at Avella will lead this session. Continuing education credit will be provided to nurses.

The patient breakout session will focus on the importance of adhering to oral chemotherapy drug treatment regimens, overcoming challenges of medication management and tips on successfully completing a medication schedule. This session will be led by Jodi Pelusi , PhD, FNP, AOCNP, Arizona Oncology – US Oncology.

Attendees will receive a free lunch. The event will conclude with a town hall question and answer session for all attendees. Panelists will include:

  • Jeffrey Schriber , MD, FRCP,  Cancer Transplant Institute
  • Denice Gibson, RN , MSN, CRNI, AOCNS, Cancer Transplant Institute at Virginia G Piper Cancer Center
  • Andrea Montoya , Certified Physician Assistant, Celgene
  • Jodi Pelusi , PhD, FNP, AOCNP, Arizona Oncology – US Oncology
  • Roxanne Parker, RN , MSN, CPN, Arizona Oncology – US Oncology
  • Eric Sredzinski , Pharm.D., AAHIVE - Avella Specialty Pharmacy

Attendees must register for the event. To register, go to Contact Devon Cramer at 602-567-7588 or for additional information.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

LLS has had a presence in Arizona since 1963, raising funds through a variety of statewide events and campaigns.  To learn more, visit or call 800-568-1372.

About Avella Specialty Pharmacy
Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy (formerly operating as The Apothecary Shops, Inc.) is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. Avella reached 1,064th on Inc. magazine's list of the 5,000 fastest-growing private companies in the country, up more than 500 places from 2011. In addition, The Arizona Corporate Excellence Awards has named Avella Specialty Pharmacy as the fastest-growing private company based in the state. For more information, please visit

SOURCE Avella Specialty Pharmacy
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
2. Burlington Coat Factory Completes Another Record Year of Supporting The Leukemia & Lymphoma Society in its Quest to Beat Cancer
3. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
4. Constellation Pharmaceuticals and The Leukemia & Lymphoma Society Partner to Develop Novel BET Inhibitor for the Treatment of Hematologic Malignancies
5. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
6. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
7. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
8. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
9. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
10. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
11. Medical Devices 2013: A Frost & Sullivan Executive MindXchange- Sustaining the Vitality of the Industry and Your Company
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):